Quick Answer: Can Prostate Cancer Be Cured?
Yes. Many localized prostate cancers—and some locally advanced or regional cancers—can be treated with curative intent.
However, “cure” depends on the cancer’s stage, Grade Group, PSA, extent on imaging, lymph-node involvement and response to treatment. It does not depend on the Gleason score or PSA alone.
For low-risk localized cancer, immediate treatment is often unnecessary because active surveillance can safely delay surgery or radiation unless the cancer shows meaningful progression.
For metastatic prostate cancer, current treatment usually aims for long-term control rather than a guaranteed cure. Modern combination therapy can nevertheless control disease for years in many men.
What Does “Cure” Mean in Prostate Cancer?
Doctors are cautious with the word cure because prostate cancer can sometimes recur years after apparently successful treatment.
In practical terms, curative treatment aims to eliminate all clinically meaningful cancer so that the patient never experiences prostate-cancer progression during his lifetime.
After treatment, doctors usually talk about:
- no evidence of disease;
- undetectable or appropriately low PSA;
- biochemical control;
- recurrence-free survival; or
- long-term cancer-specific survival
rather than guaranteeing that recurrence is impossible.
Is Localized Prostate Cancer Curable?
Very often, yes.
Localized prostate cancer is confined to the prostate and has not been shown to spread to distant organs.
Depending on risk group, curative approaches can include:
- radical prostatectomy;
- external-beam radiation therapy;
- LDR or HDR brachytherapy; and
- combined radiation and hormone therapy for cancers that need treatment intensification.
However, some localized cancers are so slow-growing that immediate curative treatment would expose the patient to side effects without improving survival.
Low-Risk Prostate Cancer: Sometimes the Best “Treatment” Is Surveillance
For many men with low-risk localized prostate cancer, current guidelines favor active surveillance.
Active surveillance does not mean ignoring cancer.
It uses planned follow-up such as:
- PSA testing;
- clinical review;
- MRI;
- repeat biopsy when indicated; and
- other risk reassessment.
If the cancer later shows clinically meaningful progression, surgery or radiation can still be offered with curative intent.
This is different from watchful waiting, which is generally used when curative treatment is unlikely to offer meaningful benefit because of limited life expectancy or other major illnesses.
Why Treating Every Early Prostate Cancer Can Be Harmful
Surgery and radiation can produce long-term side effects including:
- erectile dysfunction;
- urinary incontinence;
- urinary irritation;
- bowel/rectal problems; and
- other treatment-specific complications.
If a low-risk cancer is unlikely to threaten a man’s life, avoiding or delaying these effects can be a major benefit.
The goal is therefore not simply to “remove cancer as quickly as possible.” It is to treat the cancers that need treatment while avoiding unnecessary harm.
Intermediate-Risk Prostate Cancer
Many intermediate-risk cancers are still highly curable.
Treatment can include:
- radical prostatectomy;
- IMRT/VMAT or other modern external-beam radiation;
- selected SBRT;
- LDR/HDR brachytherapy; or
- radiation plus short-term androgen deprivation therapy (ADT) when indicated.
Favorable and unfavorable intermediate-risk disease should not be treated as identical.
For example, a small-volume Grade Group 2 cancer can behave very differently from Grade Group 3 disease.
See Gleason score and Grade Group.
High-Risk Localized Prostate Cancer Can Still Be Treated for Cure
High-risk does not automatically mean incurable.
A high-risk cancer may still be confined to the prostate or surrounding local structures.
Current treatment options include:
- radical prostatectomy in appropriately selected men as part of a potential multimodal strategy; or
- modern external-beam radiation plus long-term ADT, generally around 2–3 years.
Selected very high-risk patients may also receive additional systemic treatment such as abiraterone as part of curative-intent multimodal therapy.
Can Locally Advanced Prostate Cancer Be Cured?
Sometimes.
Locally advanced cancer has extended beyond the prostate but has not necessarily spread to distant organs.
Curative-intent treatment can still be appropriate, especially when disease remains confined to the pelvis.
Modern treatment may combine:
- prostate/pelvic radiotherapy;
- long-term ADT;
- additional systemic treatment in selected high-risk patients; and
- selected surgery within a multimodal plan.
Regional lymph-node involvement does not automatically mean distant metastatic disease.
Read our prostate cancer staging guide.
What Are the Survival Rates for Localized and Regional Disease?
The American Cancer Society currently reports the following 5-year relative survival rates for men diagnosed during 2015–2021:
| SEER stage | 5-year relative survival | Meaning |
|---|---|---|
| Localized | >99% | Cancer is confined to the prostate. |
| Regional | >99% | Cancer has spread to nearby structures or regional lymph nodes. |
| Distant | 38% | Cancer has spread to distant lymph nodes, bone or organs. |
| All stages combined | 98% | Population average across all stages. |
Does Radical Prostatectomy Cure Prostate Cancer?
Radical prostatectomy removes:
- the entire prostate;
- seminal vesicles; and
- selected lymph nodes when clinically appropriate.
It can cure localized prostate cancer when all clinically important disease is removed.
The legacy article referred to “partial prostate removal” as a main curative surgery. That is misleading.
The standard curative operation is radical prostatectomy, not removal of only part of the gland.
Focal treatments that destroy only part of the prostate are a different strategy and are not equivalent to radical prostatectomy.
Does Surgery Guarantee the Cancer Will Never Return?
No.
Even after apparently complete prostate removal, PSA may later rise because microscopic cancer cells were already outside the surgical field.
Important recurrence predictors include:
- Grade Group;
- pathological stage;
- positive lymph nodes;
- seminal-vesicle invasion;
- extraprostatic extension;
- surgical margins;
- postoperative PSA; and
- PSA doubling time if recurrence develops.
Importantly, recurrence after surgery can sometimes still be cured with early salvage radiation.
See prostate cancer recurrence and salvage treatment.
Can Radiation Cure Prostate Cancer?
Yes.
Modern radiation is a standard curative treatment for many localized and locally advanced prostate cancers.
Options include:
- IMRT/VMAT + image guidance;
- moderate hypofractionation;
- selected SBRT;
- LDR/HDR brachytherapy; and
- combined external-beam radiation and brachytherapy in selected higher-risk disease.
For unfavorable intermediate- and high-risk disease, radiation is commonly combined with ADT because randomized evidence shows better cancer outcomes.
Is Radiation Only Used After Surgery Fails?
No.
Radiation can be the first curative treatment instead of surgery.
It can also be used after surgery when:
- PSA never becomes adequately low;
- PSA begins to rise later; or
- selected adverse pathology suggests a need for additional treatment.
The old idea that surgery is always attempted first and radiation comes later is not modern prostate-cancer practice.
Does Hormone Therapy Cure Localized Prostate Cancer?
ADT alone is generally not a curative treatment for localized prostate cancer.
Its major curative-intent role is as a partner to radiation in selected intermediate-, high-risk, locally advanced and node-positive disease.
ADT suppresses testosterone signaling and improves the effectiveness of radiation in appropriate risk groups.
For high-risk localized disease, current EAU guidance generally uses 2–3 years of ADT with modern radiotherapy.
Does Chemotherapy Cure Localized Prostate Cancer?
Chemotherapy is not the routine first-line curative treatment for ordinary localized prostate cancer.
Docetaxel and other systemic therapies are used mainly in selected advanced/metastatic disease and specific high-risk treatment strategies.
The legacy article’s sequence of hormone therapy, cytotoxic drugs and chemotherapy before surgery is therefore incorrect.
Can Metastatic Prostate Cancer Be Cured?
For most men with metastatic prostate cancer, current standard therapy aims for long-term disease control rather than guaranteed cure.
Metastatic cancer means disease has spread to distant sites such as:
- bone;
- distant lymph nodes;
- lung;
- liver; or
- other organs.
Modern therapy can nevertheless produce prolonged responses.
Modern Treatment for Metastatic Hormone-Sensitive Disease
For most fit men with metastatic hormone-sensitive/castration-sensitive prostate cancer, treatment is no longer ADT alone.
Current strategies commonly use:
- ADT + abiraterone;
- ADT + apalutamide;
- ADT + enzalutamide;
- ADT + darolutamide in appropriate settings; or
- selected triplet therapy with ADT + docetaxel + an ARPI.
Selected men with low-volume newly diagnosed metastatic disease may also benefit from radiation to the prostate.
What If Metastatic Cancer Becomes Castration-Resistant?
When cancer progresses despite adequately suppressed testosterone, it is called castration-resistant prostate cancer.
ADT generally continues, while additional treatment may include:
- docetaxel or cabazitaxel;
- androgen-receptor pathway inhibitors;
- PARP-based treatments in appropriate BRCA/HRR-altered cancers;
- PSMA radioligand therapy such as Pluvicto;
- radium-223 for selected bone-predominant disease;
- sipuleucel-T in selected patients; and
- other biomarker-directed therapies.
Read our advanced prostate cancer and latest treatment guides.
Can Recurrent Prostate Cancer Still Be Cured?
Sometimes.
A rising PSA after previous treatment does not automatically mean distant metastatic disease.
After Prostatectomy
Early salvage radiotherapy can still be curative when recurrence is microscopic and confined to the prostate bed/pelvis.
Current salvage guidance emphasizes treating while PSA remains low rather than waiting for a visible mass.
After Radiation
Selected men with biopsy-proven recurrence confined to the prostate may still be candidates for:
- salvage prostatectomy;
- salvage brachytherapy;
- salvage SBRT;
- cryotherapy in selected settings; or
- HIFU in selected specialist settings.
These treatments have higher complication risks and require careful staging.
Is Focal Therapy a Prostate Cancer Cure?
Focal treatments such as HIFU or cryotherapy aim to destroy the known tumor while preserving more normal prostate tissue.
This can reduce some treatment-related effects in selected men.
However, prostate cancer is often multifocal, and long-term comparative evidence is less mature than for radical prostatectomy and radiotherapy.
Focal therapy should therefore not be advertised as a universal “less invasive cure.”
Does Early Detection Guarantee Cure?
No—but finding clinically significant cancer before distant spread can substantially expand curative options.
Screening itself does not prevent prostate cancer.
PSA screening should be based on informed shared decision-making according to age, family history, ancestry, inherited genetic risk, overall health and personal preferences.
Read our PSA screening and interpretation guide.
Does Prostate Cancer Always Need Aggressive Treatment?
No.
This is one of the most important lessons of modern prostate-cancer care.
Some cancers:
- grow so slowly that active surveillance is safer than immediate treatment;
- require curative surgery or radiation;
- need combined local + systemic treatment; or
- are metastatic and need long-term systemic control.
The treatment goal should match the actual biology and extent of disease.
Vitamin E and Selenium Do Not Prevent or Cure Prostate Cancer
The legacy page recommends vitamin E and selenium as part of a prostate-cancer prevention strategy.
Large randomized evidence shows this is wrong.
The SELECT trial found:
- selenium did not reduce prostate-cancer risk; and
- vitamin E supplementation increased prostate-cancer risk by 17% relative to placebo.
NCI therefore advises that men should not take vitamin E or selenium supplements to prevent prostate cancer.
What About Lycopene and Tomatoes?
Tomatoes are nutritious foods and can be included in a healthy diet.
But lycopene supplements have not been proven to cure prostate cancer.
A healthy prostate cancer diet can support cardiovascular, metabolic and nutritional health, but it should not be sold as an anticancer cure.
Does Stopping Smoking Help?
Yes, for overall health.
Smoking cessation reduces cardiovascular and respiratory risk and is particularly valuable for men undergoing major cancer treatment.
Observational studies have also associated smoking with less favorable prostate-cancer outcomes.
However, stopping smoking should be described as an important health and survivorship measure—not as a guaranteed prostate-cancer cure.
How Do Doctors Estimate Whether Cure Is Realistic?
Important factors include:
- Grade Group / Gleason score;
- PSA;
- TNM stage;
- number and extent of positive biopsy cores;
- MRI findings;
- PSMA PET findings where appropriate;
- regional lymph-node involvement;
- distant metastases;
- selected genomic/molecular features;
- life expectancy;
- general health; and
- response to previous treatment.
No one test provides the answer by itself.
Does PSA Becoming Undetectable Mean Cure?
It depends on treatment.
After Radical Prostatectomy
PSA should fall to a very low or undetectable level because the prostate has been removed.
A confirmed later rise can indicate biochemical recurrence.
After Radiation
The prostate remains in place, so PSA normally falls slowly and does not have to become undetectable.
A temporary PSA bounce can also occur.
The commonly used Phoenix definition of biochemical recurrence after radiation is:
PSA rise of 2 ng/mL or more above the post-treatment nadir.
Why Long-Term Follow-Up Matters
Even after curative-intent treatment, PSA follow-up remains important because recurrence can occur years later.
If recurrence is detected early, some patients still have curative salvage options.
This is especially important after prostatectomy, where early salvage radiation is more effective while PSA is still low.
Questions to Ask About Your Chance of Cure
- Is my cancer localized, regional or metastatic?
- What is my exact Grade Group?
- What is my PSA?
- What is my TNM stage?
- What does my MRI show?
- Do I need PSMA PET?
- What is my overall risk group?
- Is active surveillance safer than immediate treatment?
- If I need treatment, is the goal cure or long-term control?
- Would surgery or radiation offer similar cancer control in my case?
- Do I need ADT with radiation?
- If cancer returns, would salvage treatment still be potentially curative?
- What are the main quality-of-life tradeoffs of each option?
When a patient asks me, “Can my prostate cancer be cured?”, I would not answer from PSA or Gleason score alone. I would first look at whether the disease is confined to the prostate, involves nearby tissues or lymph nodes, or has spread to distant sites.
Many localized cancers are highly curable, but some low-risk cancers should not be treated immediately because active surveillance can avoid years of urinary or sexual side effects without losing the opportunity for cure if the disease later becomes more significant.
High-risk cancer is also not automatically incurable. When it remains localized or regional, modern multimodal treatment—such as radiation plus long-term ADT, or selected surgery followed by additional treatment when necessary—can still be given with curative intent.
Metastatic disease is different. We usually talk about long-term control rather than guaranteed cure, but modern therapies have improved substantially and population survival statistics may underestimate outcomes for men treated today.
Finally, I would never advise a patient to replace proven treatment with vitamin E, selenium, lycopene or another supplement. The aim is to match the treatment intensity to the actual cancer risk while preserving as much long-term health and quality of life as possible.
Medical References
European Association of Urology. Prostate Cancer Guidelines, 2026: active surveillance, localized/high-risk treatment, locally advanced disease, metastatic treatment and follow-up.
National Cancer Institute. Prostate Cancer Treatment PDQ: active surveillance, radical prostatectomy, external-beam radiation, brachytherapy, hormone therapy, chemotherapy, targeted therapy and metastatic treatment.
American Cancer Society. Survival Rates for Prostate Cancer, revised January 2026: localized >99%, regional >99%, distant 38% five-year relative survival for men diagnosed 2015–2021.
National Cancer Institute. Selenium and Vitamin E Cancer Prevention Trial (SELECT): selenium did not prevent prostate cancer; vitamin E alone increased prostate-cancer risk.
Last evidence update: September 2026.
Medical information notice: Whether prostate cancer is potentially curable depends on disease extent, pathology, imaging, PSA, patient health and treatment response. Population survival statistics cannot predict an individual man’s outcome.